Ionis Pharmaceuticals (IONS) News Today

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares have decreased following mixed analyst activity and insider transactions.

• Positive Sentiment: JP Morgan upgraded Ionis Pharmaceuticals, boosting analyst confidence in the stock’s outlook. JP Morgan Upgrades Ionis Pharmaceuticals (IONS)
• Positive Sentiment: A look at Ionis’s valuation highlights progress in its pipeline and positive updates from Innovation Day. Yahoo Finance Valuation Article
• Positive Sentiment: Analysts surveyed by American Banking News assigned IONS an average “Moderate Buy” rating, reflecting broad support. Average “Moderate Buy” Rating
• Positive Sentiment: MarketBeat reports a consensus “Moderate Buy” from 20 analysts, with the majority rating IONS as a buy. MarketBeat Consensus Moderate Buy
• Positive Sentiment: Needham & Company raised its price target on IONS from $70.00 to $78.00 and maintained a buy rating. Needham Price Target Raise
• Neutral Sentiment: The Globe and Mail published broader sector insights on Ionis alongside peers, offering context without a clear directional bias. Analysts Offer Insights
• Neutral Sentiment: Short interest data showed no significant change, with days-to-cover remaining effectively zero. Short Interest Update
• Negative Sentiment: CEO Brett Monia sold 437 shares at an average price of $69.26, slightly reducing his position. Brett Monia Insider Sale
• Negative Sentiment: EVP Eric Swayze sold 6,849 shares for about $472,718, cutting his stake by over 18%. Eric Swayze Insider Sale
• Negative Sentiment: EVP Patrick O’Neil sold 13,441 shares valued at $937,375, reducing his ownership by nearly 20%. Patrick O’Neil Insider Sale
• Negative Sentiment: Weiss Ratings reaffirmed a “Sell (D–)” rating on IONS, signaling continued skepticism from that shop. Weiss Ratings Sell Rating